

baseline biochemical findings? Is the renal function deterioration in pregnancy in these rats a result of hemodynamic injury or related to the systemic effects of placental dysfunction and antigenic imbalance resulting in glomerular endotheliosis? These are critical next steps to understanding the maternal and placental contributions to the observed phenotype.

In summary, we applaud the authors who pursued an animal model that mirrors the human observations. As such, this rat model of pregnancy after AKI holds promise as an important tool to further investigate the relationship between kidney function and fetal-placental development. Already, it supports our hypothesis that baseline eGFR alone, even if completely “normal” in the clinician’s eye, is insufficient to identify women with previous kidney injury who are risk for pregnancy complications. This model can hopefully be exploited further to investigate biochemical signaling pathways critical for maternal adaptation in pregnancy and placental development, to test novel therapeutics, and to inform future human clinical trials aimed at reducing the burden of maternal and fetal morbidity in women with kidney disease.

DISCLOSURES

R. Thadhani reports consultancy agreements with Fresenius Medical Care North America, Thermo Fisher, Moderna, Alnylum, Bayer, Genzyme/Sanofi, Kaneka, FDA, and Novartis; ownership interest in Aggamin LLC and Tvardi; research funding from National Institutes of Health, Kaneka Corporation, and Genzyme/Sanofi; honoraria from ThermoFisher, Roche Diagnostics, Pfizer, Merc, Pfizer, Amgen, Genzyme/Sanofi, Bayer, Alnylum, and Moderna; patents and inventions with ThermoFisher and Up-To-Date; and being a scientific advisor or member with Aggamin LLC and Vifor Pharma. The remaining author has nothing to disclose.

FUNDING

None.

ACKNOWLEDGMENTS

The content of this article reflects the personal experience and views of the author(s) and should not be considered medical advice or recommendations. The content does not reflect the views or opinions of the American Society of Nephrology (ASN) or *JASN*. Responsibility for the information and views expressed herein lies entirely with the author(s).

REFERENCES

1. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Kidney disease statistics for the United States, 2016. Available at: <https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease>. Accessed October 1, 2020
2. Bartsch E, Medcalf KE, Park AL, Ray JG; High Risk of Pre-eclampsia Identification Group: Clinical risk factors for pre-eclampsia determined in early pregnancy: Systematic review and meta-analysis of large cohort studies. *BMJ* 353: i1753, 2016

3. Zhang JJ, Ma XX, Hao L, Liu LJ, Lv JC, Zhang H: A systematic review and meta-analysis of outcomes of pregnancy in CKD and CKD outcomes in pregnancy. *Clin J Am Soc Nephrol* 10: 1964–1978, 2015
4. Odutayo A, Hladunewich M: Obstetric nephrology: Renal hemodynamic and metabolic physiology in normal pregnancy. *Clin J Am Soc Nephrol* 7: 2073–2080, 2012
5. Piccoli GB, Cabiddu G, Attini R, Vigotti FN, Maxia S, Lepori N, et al.: Risk of adverse pregnancy outcomes in women with CKD. *J Am Soc Nephrol* 26: 2011–2022, 2015
6. Garg AX, McArthur E, Lentine KL; Donor Nephrectomy Outcomes Research (DONOR) Network: Gestational hypertension and preeclampsia in living kidney donors. *N Engl J Med* 372: 1469–1470, 2015
7. Kendrick J, Holmen J, You Z, Smits G, Chonchol M: Association of unilateral renal agenesis with adverse outcomes in pregnancy: A matched cohort study. *Am J Kidney Dis* 70: 506–511, 2017
8. Tangren JS, Powe CE, Ankers E, Ecker J, Bramham K, Hladunewich MA, et al.: Pregnancy outcomes after clinical recovery from AKI. *J Am Soc Nephrol* 28: 1566–1574, 2017
9. Tangren JS, Wan Md Adnan WAH, Powe CE, Ecker J, Bramham K, Hladunewich MA, et al.: Risk of preeclampsia and pregnancy complications in women with a history of acute kidney injury. *Hypertension* 72: 451–459, 2018
10. Gillis EE, Brands MW, Sullivan JC: Adverse maternal and fetal outcomes in a novel experimental model of pregnancy after recovery from renal ischemia-reperfusion injury. *J Am Soc Nephrol* 32: 375–384, 2021

See related article, “Adverse Maternal and Fetal Outcomes in a Novel Experimental Model of Pregnancy after Recovery from Renal Ischemia-Reperfusion Injury,” on pages 375–384.

The Road Ahead for Research on Air Pollution and Kidney Disease

Ziyad Al-Aly^{1,2,3,4} and Benjamin Bowe^{1,4}

¹Clinical Epidemiology Center, Research and Development Service, Veterans Affairs St. Louis Health Care System, St. Louis, Missouri

²Department of Medicine, Washington University School of Medicine, St. Louis, Missouri

³Institute for Public Health, Washington University in St. Louis, St. Louis, Missouri

⁴Veterans Research and Education Foundation of St. Louis, St. Louis, Missouri

JASN 32: 260–262, 2021.

doi: <https://doi.org/10.1681/ASN.2020121713>

Over the past several years, substantial progress has been made in understanding the relationship between exposure to ambient

Published online ahead of print. Publication date available at www.jasn.org.

Correspondence: Dr. Ziyad Al-Aly, Clinical Epidemiology Center, Veterans Affairs St. Louis Health Care System, 915 North Grand Boulevard, 151-JC, St. Louis, MO 63106. Email: zalaly@gmail.com

Copyright © 2021 by the American Society of Nephrology

fine particulate matter (PM_{2.5}) air pollution and risk of kidney disease.^{1,2} We and others have reported that increased levels of PM_{2.5}—even at concentrations below the US National Ambient Air Quality Standards of an annual average of 12.0 $\mu\text{g}/\text{m}^3$ —were associated with increased risk of incident CKD, CKD progression, and ESKD.^{1,2} A systematic evaluation of all causes of death associated with PM_{2.5} exposure revealed a significant relationship between PM_{2.5} and risk of death due to kidney disease.³ Effort to estimate the burden of kidney disease attributable to PM_{2.5} air pollution suggested that the global burden of CKD attributable to PM_{2.5} may be substantial and disproportionately borne by low-income and lower middle-income countries.^{4,5}

However, nearly all of the evidence on the association of PM_{2.5} and kidney disease has so far been derived from studies in North America, which has relatively lower PM_{2.5} concentrations than other geographies that house much of the world's population. For example, in 2019 the average annual population-weighted PM_{2.5} was 7.66 $\mu\text{g}/\text{m}^3$ in the United States versus 83.2 and 47.7 $\mu\text{g}/\text{m}^3$ in India and China, respectively; together, India and China account for about 36% of the total world population.⁶ Studies characterizing exposure-response functions for several noncommunicable diseases suggest that the relationship between PM_{2.5} and health outcomes may not be linear. Therefore, evidence on the health effects of air pollution (including effect[s] on kidney function and disease) from countries with higher levels of PM_{2.5} than North America is needed to gain a better understanding of the magnitude of risk associated with PM_{2.5} across the spectrum of concentrations experienced by humans worldwide.

The study by Li *et al.*⁷ in this issue of *JASN* is notable in that it offers insight into the relationship between PM_{2.5} and kidney disease in China. The authors developed a cross-sectional assessment using data from the China National Survey of CKD, which included a representative sample of 47,204 Chinese adults. Exposure was assigned on the basis of estimates of PM_{2.5} spatially resolved at approximately 10 × 10 km and geocoded to each participant's residential address. The 2-year mean PM_{2.5} concentration (primary exposure) ranged from 31.3 to 87.5 $\mu\text{g}/\text{m}^3$ with a mean of 57.4 $\mu\text{g}/\text{m}^3$ —much higher than PM_{2.5} concentrations in most prior studies that examined the association of PM_{2.5} and kidney disease.^{4,5} The authors reported that increased 2-year mean ambient PM_{2.5} was associated with increased risk of prevalent CKD and prevalent albuminuria.

This study is meritorious and adds to our understanding of the relationship between high levels of PM_{2.5} and kidney disease. However, the cross-sectional design precludes it from being included in most metaregression estimates (*e.g.*, Global Burden of Disease [GBD], World Health Organization, *etc.*), and it will likely be deweighted or may not be considered by evidence synthesis panels of regulatory agencies (*e.g.*, the Integrated Science Assessment performed periodically by the US Environmental Protection Agency). The coarse spatial resolution of exposure also substantially limits the interpretation of

the findings. Nevertheless, the study provides a good launching pad to develop more optimally designed future investigations in China, other countries in East and South Asia, and beyond. In addition to broadening geographic diversity by including areas with high levels of PM_{2.5}, longitudinal cohorts leveraging exposure data with finer spatial resolution and improved methodologies will yield additional insights to deepen our understanding of the relationship between air pollutants and kidney disease.

Despite the progress made in the past several years, significant knowledge gaps remain. In addition to more robustly designed epidemiologic studies from geographies with high levels of PM_{2.5} pollution, carefully designed studies are also needed from areas with very low air pollution levels. These studies will help determine which concentrations of PM_{2.5} are safe and will inform more accurate estimation of the burden of disease attributable to PM_{2.5} exposure.

Significant advances in remote sensing technologies and exposure modeling have been made over the last decade. These have yielded better estimates not only for PM_{2.5} mass concentrations but also for individual components of PM_{2.5} with high spatial resolution. Substantial progress has also been made in causal inference methodologies, estimation of exposure-response functions (*e.g.*, Global Exposure Mortality Model), joint estimation of the health effects of PM_{2.5} and its components, and methods for source attribution.^{8,9} Leveraging these advances in exposure science and environmental epidemiology will inform more accurate health effect assessments and precision guide air pollution target setting.

Climate change—the most consequential threat facing humanity in the twenty-first century, which will likely dwarf the health and economic tolls of the coronavirus disease 2019 global pandemic—is intimately related to air pollution. Polluting energy systems are the primary drivers of both PM pollution and climate change, and PM contributes substantially to climate change through its effects on the Earth's radiative energy balance both by absorption (*e.g.*, black carbon) and by dispersion and reflection of radiation. It is unclear yet to what extent climate change and its ramifications (extreme heat, wildfires, floods, droughts, rising sea level and coastal erosion, displacement and migration, emergence of climate-sensitive novel infectious diseases, threats to terrestrial and marine food security and undernutrition, *etc.*) will shape the epidemiology of kidney disease and its upstream risk factors.¹⁰ Studies investigating the health effects of PM pollution and climate change (and potential synergetic effects on health outcomes) will also be needed.

It is also increasingly clear that racial minorities and socioeconomically disadvantaged communities are exposed to higher levels of air pollution and are at greater risk of adverse outcomes given a level of pollution exposure—compounding the risk of health loss due to PM_{2.5} exposure.¹¹ The health burdens of air pollution are unevenly distributed and disproportionately borne by populations who have contributed the least to the problem—raising a deeper question of justice.

Greater attention should be paid to enhance our understanding of these disparities and to identify actionable solutions to address them.

The inclusion of PM_{2.5}-CKD as an environmental health risk-outcome pair in future iterations of the GBD study will be an important future milestone. Realizing this goal hinges on the availability of more high-quality longitudinal studies representing different geographic areas. GBD will then produce global and national estimates of the burden of kidney disease attributable to air pollution on an ongoing basis. GBD estimates are widely used by governments to set policy priorities and allocate budget. These estimates will not only provide a more comprehensive accounting of the health effects of air pollution but will also further elevate the stature of kidney disease as an important global health problem. We must all synergize our effort to realize this important goal and to ensure that evidence generated by our scientific inquiries is serving the greater public good.

DISCLOSURES

All authors have nothing to disclose.

FUNDING

This work was supported by funds from the Institute for Public Health at Washington University in St. Louis and the US Department of Veterans Affairs.

ACKNOWLEDGMENTS

The contents do not represent the views of the US Department of Veterans Affairs or the US Government.

The content of this article reflects the personal experience and views of the author(s) and should not be considered medical advice or recommendations. The content does not reflect the views or opinions of the American Society of Nephrology (ASN) or *JASN*. Responsibility for the information and views expressed herein lies entirely with the author(s).

REFERENCES

1. Bowe B, Xie Y, Li T, Yan Y, Xian H, Al-Aly Z: Associations of ambient coarse particulate matter, nitrogen dioxide, and carbon monoxide with the risk of kidney disease: A cohort study. *Lancet Planet Health* 1: e267–e276, 2017
2. Bowe B, Xie Y, Li T, Yan Y, Xian H, Al-Aly Z: Particulate matter air pollution and the risk of incident CKD and progression to ESRD. *J Am Soc Nephrol* 29: 218–230, 2018
3. Bowe B, Xie Y, Yan Y, Al-Aly Z: Burden of cause-specific mortality associated with PM_{2.5} air pollution in the United States. *JAMA Netw Open* 2: e1915834, 2019
4. Bowe B, Artimovich E, Xie Y, Yan Y, Cai M, Al-Aly Z: The global and national burden of chronic kidney disease attributable to ambient fine particulate matter air pollution: A modelling study. *BMJ Glob Health* 5: e002063, 2020
5. Bowe B, Xie Y, Li T, Yan Y, Xian H, Al-Aly Z: Estimates of the 2016 global burden of kidney disease attributable to ambient fine particulate matter air pollution. *BMJ Open* 9: e022450, 2019
6. Health Effects Institute: State of global air 2019, 2019. Available at: www.stateofglobalair.org. Accessed February 15, 2020
7. Li G, Huang J, Wang J, Zhao M, Liu Y, Guo X, et al.: Long-term exposure to ambient PM_{2.5} and increased risk of CKD prevalence in China. *J Am Soc Nephrol* 32: 448–458, 2021
8. Burnett R, Chen H, Szyszkowicz M, Fann N, Hubbell B, Pope CA 3rd, et al: Global estimates of mortality associated with long-term exposure to outdoor fine particulate matter. *Proc Natl Acad Sci U S A* 115: 9592–9597, 2018
9. Dominici F, Zigler C: Best practices for gauging evidence of causality in air pollution epidemiology. *Am J Epidemiol* 186: 1303–1309, 2017
10. Luyckx VA, Al-Aly Z, Bello AK, Bellorin-Font E, Carlini RG, Fabian J, et al.: Sustainable development goals relevant to kidney health: An update on progress. *Nat Rev Nephrol* 17: 15–32, 2021
11. Tessum CW, Apte JS, Goodkind AL, Muller NZ, Mullins KA, Paoletta DA, et al.: Inequity in consumption of goods and services adds to racial-ethnic disparities in air pollution exposure. *Proc Natl Acad Sci U S A* 116: 6001–6006, 2019

See related article, “Long-Term Exposure to Ambient PM_{2.5} and Increased Risk of CKD Prevalence in China,” on pages 448–458.

Missing Self and DSA—Synergy of Two NK Cell Activation Pathways in Kidney Transplantation

Luis G. Hidalgo

Department of Surgery, University of Wisconsin, Madison, Wisconsin

JASN 32: 262–264, 2021.

doi: <https://doi.org/10.1681/ASN.2020121731>

Antibody-mediated rejection (ABMR) remains one of the leading causes of allograft dysfunction and kidney transplant failure. The diagnosis of ABMR relies on donor-specific antibodies (DSAs) detected in the recipient's blood, along with histopathologic features of active or chronic antibody-mediated damage evident in the graft microvasculature.¹ The prototypical lesions of ABMR are those of microvascular inflammation (MVI). Gene expression characteristics of endothelial activation and capillary deposition of complement breakdown product C4d are also regularly observed and are evident of immune attack on graft endothelial cells. Overall, the morphologic phenotype of ABMR indicates that DSA binds onto targets

Published online ahead of print. Publication date available at www.jasn.org.

Correspondence: Dr. Luis G. Hidalgo, Department of Surgery, University of Wisconsin, 448 Science Drive, Suite 250, Madison, WI 53711. Email: hidalgo@surgey.wisc.edu

Copyright © 2021 by the American Society of Nephrology